Long-Circulating Liposome Synthesis Service

Introduction to Our Long-Circulating Liposome Synthesis Service

In the realm of drug delivery and biomolecular encapsulation, the ability to prolong circulation time of active agents in systemic circulation without rapid clearance is paramount. At BOC Sciences, our custom long-circulating liposome synthesis service is engineered to meet the highest standards of pharmacokinetic optimization and targeted delivery. By leveraging our two decades of expertise in lipid nanotechnology and surface modification strategies, we deliver precision-engineered liposomal systems that are specifically tailored to achieve extended in vivo half-life, low immunogenicity, and controlled release profiles. In addition, you have access to a full range of custom liposome services at BOC Sciences.

How to Get Started with Us?

  • Reach out to us via our website or email to discuss your custom long-circulating liposome synthesis project.
  • We'll arrange a meeting to review your specific drug delivery goals, formulation needs, and scientific requirements.
  • Our experts will evaluate the feasibility of your project, considering factors like drug type, encapsulation methods, and stability.
  • We'll provide a customized development plan, including estimated timelines, cost breakdowns, and project milestones.
  • Upon agreement of the terms, we'll finalize the contract and initiate the synthesis process, guiding you through every step with our expert support.

Request A Quote

Contact us to discuss how we can help you achieve your research goals

Price Inquiry

What are Long-Circulating Liposomes?

Prolonged systemic circulation remains one of the most critical challenges in nanomedicine design. At BOC Sciences, our Custom Long-Circulating Liposome Synthesis Service addresses this need with tailored solutions that optimize pharmacokinetics, enhance drug bioavailability, and facilitate targeted delivery. Leveraging two decades of expertise in lipid-based nanocarriers and preclinical formulation development, we empower researchers with robust and scalable liposome systems engineered for extended in vivo residence times.

Advantages of Long-Circulating Liposomes in Drug Delivery

  • Prolonged Systemic Retention: PEGylation significantly reduces opsonization and uptake by macrophages, extending circulation time from hours to days, depending on the lipid composition and surface modifications.
  • Targeted Accumulation: Through passive targeting mechanisms, these liposomes accumulate preferentially in pathological tissues characterized by leaky vasculature, such as tumors or infection sites.
  • Reduced Off-Target Toxicity: By avoiding premature drug release and minimizing exposure to healthy tissues, long-circulating liposomes mitigate systemic side effects—particularly critical in cytotoxic therapies.
  • Controlled Release Kinetics: Tailorable lipid bilayer composition and polymer modifications enable fine-tuning of release profiles, facilitating sustained and site-specific delivery.
  • High Encapsulation Efficiency: Suitable for both hydrophilic and lipophilic payloads, with optimization for challenging APIs including nucleic acids, peptides, and chemotherapeutics.

Comprehensive Service for Long-Circulating Liposome Synthesis

BOC Sciences delivers a highly customized, science-driven platform for long-circulating liposome synthesis. Designed for researchers seeking precise control over nanocarrier behavior, our service goes far beyond standard formulations by offering an extensive toolkit of lipid chemistries, encapsulation strategies, and surface modifications—all engineered for optimal pharmacokinetic performance.

Rational Lipid Composition Engineering

We provide full control over the lipid bilayer architecture, carefully balancing fluidity, rigidity, and permeability to suit the physicochemical nature of your active compound. Options include:

  • Saturated and unsaturated phospholipids (e.g., DSPC, HSPC, DOPC) to fine-tune bilayer stability.
  • Cholesterol modulation to reduce leakage and enhance mechanical strength.
  • Custom molar ratios of lipid components to optimize bilayer phase transition temperatures (Tm) for stability under physiological conditions.

Surface PEGylation & Functionalization

Our PEGylation strategies are not one-size-fits-all for long-circulating liposome synthesis. We tailor the:

  • PEG chain length (PEG500–PEG5000) for fine control over stealth properties and particle hydration.
  • Surface density of PEGylated lipids to balance MPS evasion and cellular uptake.
  • Anchoring moieties (e.g., DSPE-PEG, cholesterol-PEG conjugates) to ensure optimal membrane integration without compromising bilayer integrity.
  • Optional ligand functionalization (e.g., folate, RGD peptides, aptamers) for receptor-mediated targeting while maintaining long-circulation behavior.

Sophisticated Drug Loading Capabilities

  • Hydrophilic Payloads: Encapsulated in the aqueous core through passive hydration or remote loading (e.g., ammonium sulfate gradient).
  • Hydrophobic Compounds: Integrated into the lipid bilayer using ethanol injection or thin-film rehydration.
  • Amphiphilic Molecules: Dual localization through customized formulation techniques.
  • Controlled Co-Encapsulation: Simultaneous delivery of synergistic drug combinations with different release profiles.

Multi-Responsive Encapsulation Designs

We offer multi-Level encapsulation long-circulating liposomes for advanced delivery goals:

  • Dual or sequential drug encapsulation strategies for combination therapies.
  • Co-delivery of hydrophilic and hydrophobic compounds via core/shell architecture.
  • pH-sensitive systems for tumor microenvironment activation.
  • Redox-responsive liposomes for intracellular drug release.
  • Thermosensitive liposomes compatible with hyperthermia-assisted delivery protocols.

Scalable and Versatile Manufacturing

From early-stage discovery to preclinical development, our synthesis process is adaptable to a range of batch sizes and regulatory expectations:

  • R&D-scale (milligram to gram) to pilot and preclinical-scale synthesis (multi-gram to tens of grams).
  • Lyophilization and cryoprotection options available for enhanced stability and logistics.

Value-Added Support

BOC Sciences' service doesn't end at delivery. We offer:

  • Comprehensive formulation consultation with senior lipid scientists.
  • Data-rich reporting including encapsulation efficiency, particle stability curves, release kinetics, and biocompatibility profiles.
  • Optional stability studies under accelerated and long-term storage conditions.

Step-by-Step Process of Long-Circulating Liposome Synthesis Service

At BOC Sciences, we follow a meticulously structured, step-by-step process to ensure that each liposomal vaccine formulation meets the highest standards of quality, functionality, and performance. Our process encompasses everything from initial consultations to advanced liposome characterization and formulation optimization.

1. Project Evaluation & Technical Consultation

Our team of lipid formulation experts conducts an in-depth assessment of your molecule's physicochemical properties, therapeutic goals, and delivery requirements to devise a precise liposome development roadmap.

2. Long-Circulating Liposomal Formulation & Surface Modification

We systematically screen and optimize:

  • Phospholipid species and molar ratios
  • PEG chain length and density
  • pH-sensitive or enzyme-cleavable modifications (for triggered release)

This phase includes iterative prototyping to balance circulation half-life, encapsulation efficiency, and release profiles.

3. Encapsulation Efficiency Testing & Particle Size Control

  • Dynamic Light Scattering (DLS) to measure particle size distribution (targeting<120 nm with PDI <0.2)
  • Zeta Potential Analysis for colloidal stability prediction
  • UV-VIS or fluorescence quantification to measure drug loading and entrapment efficiency

4. Quality Characterization & Data Delivery

Comprehensive physicochemical and structural validation is performed:

  • HPLC/LC-MS for drug quantification
  • Cryo-TEM for morphological integrity
  • Stability profiling under accelerated and real-time storage conditions

Complete technical reports and raw data are provided for regulatory readiness and data traceability.

Benefits of Our Long-Circulating Liposome Synthesis Service

Applications of Our Long-Circulating Liposome Synthesis Service

BOC Sciences' custom long-circulating liposomes are engineered for precision delivery of therapeutic agents in challenging preclinical settings.

Oncology Drug Delivery and Tumor Targeting

Long-circulating liposomes are extensively utilized in solid tumor therapy, taking advantage of the Enhanced Permeability and Retention (EPR) effect. The PEGylated lipid coating enables prolonged systemic circulation, increasing the likelihood of accumulation in tumor tissue via leaky vasculature and impaired lymphatic drainage.

  • Encapsulation of cytotoxic agents (e.g., doxorubicin, paclitaxel) for improved therapeutic index and reduced cardiotoxicity.
  • pH-sensitive liposomes for tumor-specific drug release in acidic microenvironments.
  • Co-delivery of chemotherapeutics and resistance modulators (e.g., verapamil, siRNA) to overcome multi-drug resistance (MDR) phenotypes.

Our service allows precise control of particle size (80–100 nm) and PEG surface density, which are critical for achieving optimal tumor penetration and retention.

Delivery of Nucleic Acid Therapeutics (mRNA, siRNA, miRNA, CRISPR components)

Long-circulating liposomes offer a non-viral and biocompatible delivery platform for fragile genetic materials. Their extended circulation enables extrahepatic tissue delivery, an ongoing challenge in RNA therapeutics.

  • Protection of nucleic acids from serum nucleases and renal clearance.
  • Targeted delivery to spleen, lymph nodes, or tumor tissue using surface-ligand conjugation (e.g., antibodies, aptamers).
  • Encapsulation of CRISPR-Cas9 RNPs with endosomal escape facilitation for genome editing studies.

BOC Sciences can formulate liposomes with cationic or ionizable lipids tailored for nucleic acid complexation, combined with long-circulating properties for systemic administration in preclinical gene therapy models.

Inflammation-Targeted Therapies and Autoimmune Modulation

Inflamed tissues, similar to tumors, exhibit vascular leakage—making them accessible to long-circulating nanocarriers.

  • Steroid or NSAID-loaded PEG-liposomes enable prolonged anti-inflammatory effects in rheumatoid arthritis, colitis, and atherosclerosis models.
  • Reduced systemic immunosuppression due to preferential localization at the site of inflammation.
  • Enhanced efficacy in combination with biologics through co-delivery strategies.

We optimize PEG chain length and charge neutrality to evade uptake by non-inflamed tissues and to maximize accumulation in pathological sites.

Theranostics and Image-Guided Drug Delivery

Long-circulating liposomes can be engineered to carry diagnostic agents alongside therapeutics, enabling simultaneous imaging and treatment.

  • Gadolinium or fluorophore encapsulation for MRI or optical tracking of drug biodistribution.
  • Real-time pharmacokinetic monitoring in animal models.
  • Triggerable release mechanisms for on-demand payload release upon imaging cue.

BOC Sciences integrates diagnostic moieties into the liposomal bilayer or aqueous core, without compromising circulation half-life or drug stability.

Vaccine Delivery and Immunomodulation

Long-circulating liposomes are increasingly applied in vaccine design due to their ability to sustain antigen presentation and modulate immune responses.

  • Co-encapsulation of antigens and adjuvants for synergistic immunostimulation.
  • Targeted delivery to antigen-presenting cells (APCs) with stealth features to avoid premature clearance.
  • pH-sensitive formulations to enhance cytosolic antigen release and cross-presentation.

Our service supports tailored surface functionalization (e.g., mannose, peptides) for dendritic cell targeting and PEGylation level adjustments to balance immune evasion and immune activation.

FAQs – Insights about Our Long-Circulating Liposome Synthesis Service

Product

What is the typical circulation time for PEGylated liposomes?

Depending on the lipid composition and PEG density, circulation times can extend beyond 48 hours in vivo, especially with optimized stealth formulations.

Can targeting ligands be added to PEGylated liposomes?

Yes. We offer ligand conjugation (e.g., antibodies, peptides, aptamers) using functionalized PEG linkers (e.g., maleimide-PEG-DSPE), balancing targeting efficiency with circulation longevity.

How is the optimal PEG length and density determined?

We analyze the intended circulation time, compound stability, and application to fine-tune PEG chain lengths (commonly PEG2000–5000) and molar ratios, balancing stealth properties and biological interactions.

Can you co-encapsulate hydrophilic and hydrophobic drugs?

Yes, our formulations allow dual-drug loading using multi-compartment designs or sequential encapsulation protocols with validated separation of payloads.

Can you provide lyophilized (freeze-dried) long-circulating liposomes?

Yes, we offer lyophilization services with cryoprotectant optimization (e.g., sucrose, trehalose) to ensure the structural and functional integrity of liposomes post-reconstitution.

What types of PEG-lipids do you offer for formulation?

We stock a broad portfolio of PEGylated lipids, including DSPE-PEG2000, DSPE-PEG5000, mPEG-DSPE, DSPE-PEG-Mal, and custom-synthesized PEG-lipids with functional terminal groups for modular surface modifications.

By integrating materials science, pharmaceutical chemistry, and nanobiotechnology, BOC Sciences delivers long-circulating liposomes that are not only customized but also scientifically optimized—ready for preclinical advancement and beyond.

Supplementary Knowledges: Long-Circulating Liposomes & Lipid Nanoparticles

How do long-circulating liposomes work?

Long-circulating liposomes are designed with a stealth surface typically modified with polyethylene glycol (PEG), which prevents recognition and clearance by the reticuloendothelial system (RES). This modification allows them to stay in the bloodstream for an extended period, enabling prolonged circulation and improved targeting to specific tissues, such as tumors or inflamed sites. The liposomes gradually release their payload in response to environmental triggers or target-specific interactions, enhancing therapeutic efficacy while reducing systemic side effects.

What is the long-circulating lipid nanoparticle (LNP)?

A long-circulating lipid nanoparticle (LNP) is a nanoscale delivery system composed of lipids, often including PEGylated lipids, that are engineered to remain in circulation for extended periods. The PEG coating helps evade immune clearance, allowing the particles to circulate through the bloodstream, reach targeted tissues, and deliver encapsulated drugs, nucleic acids, or other therapeutics with increased bioavailability and reduced off-target effects. LNPs are widely used for gene delivery and RNA-based therapies due to their ability to protect sensitive molecules and facilitate cellular uptake.

Your Liposome CDMO Partner, Empowering Innovative Drug Development.

Contact Us

USA
  • International :
    US & Canada (Toll free):
  • Fax:
  • Email:

Europe

  • Tel:
  • Email:

Products

Solutions

Copyright ©  2025  BOC Sciences. All rights reserved.

Inquiry Basket
Loading ......
Delete selected Go to checkout